Arcus Biosciences Valuation
| RCUS Stock | USD 14.70 0.42 2.94% |
At this time, the firm appears to be undervalued. Arcus Biosciences shows a prevailing Real Value of $21.21 per share. The current price of the firm is $14.7. Our model approximates the value of Arcus Biosciences from analyzing the firm fundamentals such as return on equity of -0.5, and Profit Margin of (1.03) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Arcus Biosciences' valuation include:
Price Book 2.368 | Enterprise Value 306.9 M | Enterprise Value Ebitda 3.9599 | Price Sales 4.9688 | Enterprise Value Revenue 1.1669 |
Undervalued
Today
Please note that Arcus Biosciences' price fluctuation is not too volatile at this time. Calculation of the real value of Arcus Biosciences is based on 3 months time horizon. Increasing Arcus Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Arcus stock is determined by what a typical buyer is willing to pay for full or partial control of Arcus Biosciences. Since Arcus Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arcus Stock. However, Arcus Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.7 | Real 21.21 | Target 43.08 | Hype 14.52 | Naive 14.64 |
The intrinsic value of Arcus Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Arcus Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Arcus Biosciences helps investors to forecast how Arcus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arcus Biosciences more accurately as focusing exclusively on Arcus Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Arcus Biosciences' intrinsic value based on its ongoing forecasts of Arcus Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Arcus Biosciences' closest peers.
Arcus Biosciences Cash |
|
Arcus Valuation Trend
Arcus Biosciences' real value is important for investors to make better decisions and a more accurate overall view of Arcus Biosciences' financial worth over time. Using both Arcus Biosciences' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Arcus Revenue by Product
Arcus Biosciences Total Value Analysis
Arcus Biosciences is at this time anticipated to have valuation of 306.9 M with market capitalization of 1.31 B, debt of 11 M, and cash on hands of 1.05 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Arcus Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
306.9 M | 1.31 B | 11 M | 1.05 B |
Arcus Biosciences Investor Information
About 40.0% of the company outstanding shares are owned by corporate insiders. The book value of Arcus Biosciences was at this time reported as 6.18. The company recorded a loss per share of 3.19. Arcus Biosciences had not issued any dividends in recent years. Based on the key indicators related to Arcus Biosciences' liquidity, profitability, solvency, and operating efficiency, Arcus Biosciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Arcus Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arcus Biosciences has an asset utilization ratio of 10.68 percent. This implies that the Company is making $0.11 for each dollar of assets. An increasing asset utilization means that Arcus Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Arcus Biosciences Ownership Allocation
Arcus Biosciences holds a total of 91.51 Million outstanding shares. Over half of Arcus Biosciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Arcus Biosciences Profitability Analysis
The company reported the previous year's revenue of 117 M. Net Loss for the year was (307 M) with loss before overhead, payroll, taxes, and interest of (176 M).About Arcus Biosciences Valuation
The stock valuation mechanism determines Arcus Biosciences' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Arcus Biosciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Arcus Biosciences. We calculate exposure to Arcus Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Arcus Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -223 M | -211.8 M | |
| Pretax Profit Margin | (2.57) | (2.70) | |
| Operating Profit Margin | (2.91) | (3.05) | |
| Net Loss | (2.62) | (2.76) | |
| Gross Profit Margin | (1.91) | (2.00) |
Arcus Biosciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Arcus Biosciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 74 M |
Arcus Biosciences Current Valuation Indicators
Arcus Biosciences' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Arcus Biosciences' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Arcus Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Arcus Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Arcus Biosciences' worth.Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.